Registration

AGenda

Welcome Day

Thursday, August 1, 2024

New-York Historical Society, Lobby

6:00 PM - 9:00 PM

World GU Poster Presentation & Welcome Reception

Day One

Friday, August 2, 2024

Breakfast Symposium (Non-CE)

New-York Historical Society

7:30 AM - 8:20 AM

Prostate Cancer: Applying the Goldilocks Principle in Advanced Prostate Cancer: Matching Disease Aggressiveness and Treatment Intensity to Optimize Outcomes

Chair: Alicia Morgans, MD, MPH

New-York Historical Society, General Session

8:45 AM

A Case Of Barriers And MDT Impact In The Treatment Of Advanced Prostate Cancer

Mark Fleming, MD // Virginia Oncology Associates

8:55 AM

Racial Disparities in Prostate Cancer Care

Brandon Mahal, MD // University of Miami

9:05 AM

Updates in High-Risk Hormone Sensitive Biochemical Recurrence

Neal Shore, MD, FACS // Atlantic Urology Clinics

9:15 AM

Oligometastatic Prostate Cancer: MDT approach - Surgeons Perspective

James Eastham, MD, FACS // Memorial Sloan Kettering Cancer Center

9:25 AM

Oligometastatic and Oligoprogressive Disease - Radiation Oncology Perspective

Paul Nguyen, MD, MBA // Dana-Farber Cancer Institute

9:35 AM

Debate: Doublet vs Triplet Therapy in mCSPC

Tanya Dorff, MD // City of Hope

Pedro Barata, MD // Case Western Reserve University

10:00 AM

Q&A

10:15 AM

Close

Networking Break

New-York Historical Society, Lobby

10:15 AM - 10:45 AM

Prostate Cancer: Hot off the FDA presses: Thinking through therapeutic advances and recent approvals in mCRPC

Chair: Alicia Morgans, MD, MPH

New-York Historical Society, General Session

10:45 AM

Targeting The Immune Response in mCRPC

Karen Autio, MD, MPH // Memorial Sloan Kettering Cancer Center

10:55 AM

Updates In Current Approaches To Radioligand Therapy in mCRPC

Elisabeth Heath, MD, FACP // Karmanos Cancer Center

11:05 AM

Next Generation Radioligand Therapies in mCRPC

Praful Ravi, MB, Bchir, MRCP // Dana-Farber Cancer Institute

11:15 AM

Novel AR-Targeted Approaches to Treatment of mCRPC

Matthew Smith, MD, PhD // Massachusetts General Hospital

11:25 AM

Debate: PARPinhibitor Combinations in mCRPC - Pro vs Con

Neeraj Agarwal, MD // Huntsman Cancer Institute

Charles Ryan, MD // University of Minnesota

11:50 AM

Q&A

12:05 AM

Close

Lunch Symposium (Non-CE)

New-York Historical Society

12:10 PM - 1:10 PM

Special Session

Chair: Jahan Aghalar, MD

New-York Historical Society

1:30 PM - 1:50 PM

Leading the Way in Community oncology: an Interview with Dr. Jeff Vacirca

Renal Cell Carcinoma: In the Right Space at the Right Time: Idealized Management of Kidney Cancer

Chair: Daniel George, MD

New-York Historical Society, General Session

1:50 PM

A Case for Adjuvant Treatment in Renal Cell Carcinoma

Vasily Assikis, MD // Piedmont Cancer Institute

2:00 PM

Patient Selection for Adjuvant Treatment and Trials

Naomi Haas, MD // University of Pennsylvania

2:10 PM

Molecular Markers of Microscopic Disease in RCC

David Braun, MD, PhD // Yale Cancer Center

2:20 PM

Debate: Upfront vs Delayed Nephrectomy For Low-Volume Metastatic RCC

Brant Inman, MD, MS, FRCSC // Western University, Canada

Bradley McGregor, MD // Dana-Farber Cancer Institute

2:45 PM

Consolidative Focal Therapy in RCC

Ulka Vaishampayan, MD // University of Michigan

2:55 PM

Q&A

3:10 PM

Close

Networking Break

New-York Historical Society, Lobby

3:10 PM - 3:40 PM

Renal Cell Carcinoma: Remixing the Management of Metastatic Renal Cell Carcinoma

Chair: Daniel George, MD

New-York Historical Society, General Session

3:40 PM

How Do We Risk Stratify Beyond IMDC in mRCC?

Katy Beckermann, MD, PhD // Vanderbilt-Ingram Cancer Center

3:50 PM

Management of Favorable Risk RCC: Goals and Treatment Endpoints

Michael Harrison, MD // Duke Cancer Center

4:00 PM

Debate: IO/IO vs IO/TKI in the Treatment of Intermediate-Risk RCC

David McDermott, MD // Beth Israel Deaconess Medical Center

Rana McKay, MD // University of California San Diego

4:25PM

Sequential vs Concomitant Therapies in mRCC

Tian Zhang, MD // UT Southwestern Medical Center

4:35PM

Novel Agents in mRCC: Where Do We Introduce?

Eric Jonasch, MD, PhD // UT MD Anderson Cancer Center

4:45PM

Q&A

5:00PM

Close

Keynote Presentation (Non-CE)

New-York Historical Society

5:00 PM - 5:45 PM

Day Two

Saturday, August 3, 2024

Breakfast Symposium (Non-CE)

New-York Historical Society

7:30 AM - 8:20 AM

Featured Session: THE UROMIGOS - The Intersection of Clinical Trials & Community Practice

New-York Historical Society, General Session

8:30 AM - 10:30 AM

Brian Rini, MD, FASCO // Vanderbilt-Ingram Cancer Center

Thomas Powles, MD // Barts Cancer Centre

Networking Break

New-York Historical Society, Lobby

10:30 AM - 11:00 AM

Tools For Today's Oncologist

Chair: Talha Shaikh, MD, MBA

New-York Historical Society, General Session

11:00 AM

Testing & Biomarkers in Genitourinary Cancers

Thomas Stricker, MD // OneOncology

11:10 AM

Social Media for the Oncologist

Neeraj Agarwal, MD // Huntsman Cancer Institute

11:20 AM

HealthCare Policy

Ted Okon, MBA // Community Oncology Alliance

11:35 AM

New York Cancer & Blood Specialists/Memorial Sloan Kettering Cancer Center Collaboration Highlights & Best Practices

Jeffrey Vacirca, MD, FACP // New York Cancer & Blood Specialists

Collaboration Partner - TBD // Memorial Sloan Kettering Cancer Center

11:50 AM

Q&A

12:00 PM

Close

Lunch Symposium (Non-CE)

New-York Historical Society

12:10 PM - 1:15 PM

Bladder Cancer: Multidisciplinary Management of Localized Bladder Cancer

Chair: Shilpa Gupta, MD

New-York Historical Society, General Session

1:20 PM

IBCG Consensus Update on Bladder Preservation in MIBC

Shilpa Gupta, MD // Cleveland Clinic

1:30 PM

Bladder Preservation After Neoadjuvant Treatment in MIBC

Sima Porten, MD, MPH // University of California San Francisco

1:40 PM

Future of Perioperative Therapy in Bladder Cancer

Matthew Galsky, MD // Mount Sinai Health System

1:50 PM

NMIBC - Defining Trial Endpoints

Ashish Kamat, MD, MBBS // MD Anderson Cancer Center

2:00 PM

NMIBC- Novel Bladder Sparing Treatments

Sia Daneshmand, MD // University of Southern California

2:10 PM

A Case For Bladder Preservation

Michael Lattanzi, MD // Texas Oncology

2:20 PM

Debate: Chemo-RT vs Radical Cystectomy in the Treatment of MIBC

Jason Efstathiou, MD, DPhil // Massachusetts General Hospital

John Sfakianos, MD // Icahn School of Medicine at Mount Sinai

2:45 PM

Q&A

3:00 PM

Close

Networking Break

New-York Historical Society, Lobby

3:00 PM - 3:30 PM

Bladder Cancer - What’s New in the Management of Bladder Cancer: Where do we go next?

Chair: Shilpa Gupta, MD

New-York Historical Society, General Session

3:30 PM

A Case for Selection & Sequencing in Bladder Cancer

Daniel Vaena, MD // West Cancer Center & Research Institue

3:40 PM

Choosing First-Line Systemic Treatment in Bladder Cancer

Guru Sonpavde, MD // AdventHealth Cancer Institute

3:50 PM

Sequencing of Therapies in the Evolving Paradigm

Parminder Singh, MD // Mayo Clinic Cancer Center

4:00 PM

Role of Biomarkers in Bladder Cancer

Matthew Milowsky, MD, FASCO // University of North Carolina

4:10 PM

Optimizing Dosing of ADCs and Management of Adverse Events In Bladder Cancer

Sandy Srinivas, MD // Stanford Cancer Center

4:20 PM

Trial Development in Rare Variant Histologies

Andrea Apolo, MD // National Institutes of Health

4:30 PM

Future Of ADCs And Targeted Therapies in mUC

Jonathan Rosenberg, MD // Memorial Sloan Kettering Cancer Center

4:40 PM

Q&A

5:00 PM

Close

Farewell Reception

New-York Historical Society, Lobby

5:00 PM - 7:00 PM

*Agenda is subject to change.

Experience New York

Come for the education.

Stay for the fun.